(Last)

(Street)

(City)

CAMBRIDGE

1. Title of Security (Instr. 3)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ngton, D.C. 20549	OMB APPROVA

wasnington, D.C. 20549	OMB APPROVAL		
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287	

231111gton, D.C. 20040		

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person

(First)

MA

(State)

3. Transaction

C/O ELEVEN BIOTHERAPEUTICS, INC. 245 FIRST STREET, SUITE 1800

(Middle)

02142

(Zip)

3A. Deemed

HURLY STEPHEN A

Filed pursuant to Section 16(a) or Section 30(h) of the In

pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940		Estimated average burder hours per response:	0.5				
2. Issuer Name and Ticker or Trading Symbol Eleven Biotherapeutics, Inc. [EBIO]	(Check all applicable X Director	10% Ov	vner				
3. Date of Earliest Transaction (Month/Day/Year) 03/14/2018	- X Officer (giv below) Pr	specify					
4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
	X Form filed	by One Reporting Person	ı				
	Form filed Person	by More than One Report	ting				

2. Transaction Date 2A. Deemed Execution Date, 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership Form: Direct 5. Amount of Securities 7. Nature of Transaction Indirect if any (Month/Day/Year) (Month/Day/Year) Code (Instr. Beneficially (D) or Indirect **Beneficial** Ownership (Instr. 4) 8) Owned Following Reported (A) or (D) Transaction(s) Code Amount Price (Instr. 3 and 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

5. Number of

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security		Execution Date, if any (Month/Day/Year)	Transa Code (8)		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported	Direct (D)	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Common Stock	\$1.59	03/14/2018		A		105,000 ⁽¹⁾		03/14/2018	10/03/2027	Common Stock	105,000	\$0	105,000	D	

Explanation of Responses:

1. On October 4, 2017, the reporting person was granted an option to purchase 420,000 shares of common stock. This option vests in installments based on the achievement of certain strategic and clinical milestones. On March 14, 2018, the Compensation Committee of the Board of Directors of the Company determined that one of these performance milestones was met, resulting in vesting of the option with respect to 105,000

Remarks:

1. Title of 2.

03/16/2018 /s/ Stephen A. Hurly

** Signature of Reporting Person Date

6. Date Exercisable and 7. Title and Amount 8. Price of 9. Number of 10.

11. Nature

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.